These observations came from a preclinical in vivo study, which also demonstrated that IL6 ablation abolished the observed sex differences in hepatocarcinogenesis, suggesting IL6 as a pharmacological target for HCC [25]. This evidence concerns the gene IL6 and hepatocellular carcinoma.